Patompong Ungprasert1,2, Narat Srivali3, Charat Thongprayoon4. 1. Division of Rheumatology, Department of Medicine (Ungprasert), Mayo Clinic, Rochester, Minnesota. 2. Department of Medicine (Ungprasert), Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 3. Division of Critical Care and Pulmonary Medicine, Department of Medicine (Srivali, Mayo Clinic, Rochester, Minnesota. 4. Division of Nephrology and Hypertension, Department of Medicine (Thongprayoon), Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: The association between the development of heart failure (HF) and use of nonsteroidal anti-inflammatory drugs (NSAIDs) is not well established. HYPOTHESIS: Use of NSAIDs may increase the risk of incident HF. METHODS: We conducted a systematic review and meta-analysis of observational studies that reported odds ratio, relative risk, hazard ratio, or standardized incidence ratio comparing risk of incident HF in NSAID users vs nonusers. Pooled risk ratios (RR) and 95% confidence intervals (CI) for all NSAIDs and both subclasses (conventional NSAIDs and highly selective cyclooxygenase-2 inhibitors [COXIBs]) were calculated using a random-effect, generic inverse variance method. RESULTS: Seven studies with 7,543,805 participants were identified and included in our data analysis. Use of NSAIDs was associated with a significantly higher risk of developing HF, with a pooled RR of 1.17 (95% CI: 1.01-1.36). Subgroup analysis showed a significantly elevated risk among users of conventional NSAIDs (RR: 1.35, 95% CI: 1.15-1.57) but not users of COXIBs (RR: 1.03, 95% CI: 0.92-1.16). CONCLUSIONS: A significantly elevated risk of incident HF was observed among users of NSAIDs.
BACKGROUND: The association between the development of heart failure (HF) and use of nonsteroidal anti-inflammatory drugs (NSAIDs) is not well established. HYPOTHESIS: Use of NSAIDs may increase the risk of incident HF. METHODS: We conducted a systematic review and meta-analysis of observational studies that reported odds ratio, relative risk, hazard ratio, or standardized incidence ratio comparing risk of incident HF in NSAID users vs nonusers. Pooled risk ratios (RR) and 95% confidence intervals (CI) for all NSAIDs and both subclasses (conventional NSAIDs and highly selective cyclooxygenase-2 inhibitors [COXIBs]) were calculated using a random-effect, generic inverse variance method. RESULTS: Seven studies with 7,543,805 participants were identified and included in our data analysis. Use of NSAIDs was associated with a significantly higher risk of developing HF, with a pooled RR of 1.17 (95% CI: 1.01-1.36). Subgroup analysis showed a significantly elevated risk among users of conventional NSAIDs (RR: 1.35, 95% CI: 1.15-1.57) but not users of COXIBs (RR: 1.03, 95% CI: 0.92-1.16). CONCLUSIONS: A significantly elevated risk of incident HF was observed among users of NSAIDs.
Authors: Lisa B Signorello; Joseph K McLaughlin; Loren Lipworth; Søren Friis; Henrik Toft Sørensen; William J Blot Journal: Am J Ther Date: 2002 May-Jun Impact factor: 2.688
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: W G Bensen; S Z Zhao; T A Burke; R A Zabinski; R W Makuch; C J Maurath; N M Agrawal; G S Geis Journal: J Rheumatol Date: 2000-08 Impact factor: 4.666
Authors: Muhammad Mamdani; David N Juurlink; Douglas S Lee; Paula A Rochon; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis; Therese A Stukel Journal: Lancet Date: 2004-05-29 Impact factor: 79.321
Authors: Gary C Curhan; Andrea J Bullock; Susan E Hankinson; Walter C Willett; Frank E Speizer; Meir J Stampfer Journal: Pharmacoepidemiol Drug Saf Date: 2002-12 Impact factor: 2.890
Authors: Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba Journal: Med Res Rev Date: 2018-01-05 Impact factor: 12.944
Authors: Amy Barton Pai; Joseph A Vassalotti; Chester H Fox; Jennifer K Carroll; Gerald E Pulver; L Miriam Dickinson; Wilson D Pace Journal: Kidney360 Date: 2020-04-07
Authors: Cyrus Cooper; Roland Chapurlat; Nasser Al-Daghri; Gabriel Herrero-Beaumont; Olivier Bruyère; François Rannou; Roland Roth; Daniel Uebelhart; Jean-Yves Reginster Journal: Drugs Aging Date: 2019-04 Impact factor: 3.923
Authors: Che Suraya Zin; Nor Ilyani Nazar; Norny Syafinaz Rahman; Nor Elina Alias; Wan Rohaidah Ahmad; Nurul Sahida Rani; Mary Suma Cardosa; Kim Swan Ng; Felicia Loh Ye Journal: J Pain Res Date: 2018-09-20 Impact factor: 3.133